Aleglitazar

Aleglitazar is a pharmaceutical drug that was under development by Roche for the treatment of Type 2 diabetes. It belongs to the class of drugs known as dual PPAR agonists, which target the peroxisome proliferator-activated receptors (PPARs) alpha and gamma.

Development and Clinical Trials[edit | edit source]

Aleglitazar was in Phase III clinical trials when development was halted in 2013. The decision was made following an interim analysis of the AleCardio trial, which was designed to evaluate the efficacy and safety of aleglitazar in patients with a recent acute coronary syndrome event and type 2 diabetes. The analysis revealed that the drug did not show an acceptable efficacy/safety profile compared to the current standard of care.

Mechanism of Action[edit | edit source]

As a dual PPAR agonist, aleglitazar works by activating both PPAR-alpha and PPAR-gamma receptors. PPAR-alpha activation increases high-density lipoprotein (HDL) cholesterol and decreases triglycerides, while PPAR-gamma activation improves insulin sensitivity and lowers blood glucose levels.

Potential Risks and Side Effects[edit | edit source]

Potential risks and side effects associated with aleglitazar include edema, heart failure, renal impairment, hypoglycemia, and weight gain. These side effects are similar to those seen with other drugs in the thiazolidinedione class, which also target PPAR-gamma.

See Also[edit | edit source]

Aleglitazar Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.